Disease landscape
Diabetes Mellitus
Severe to moderate limitations in access to diabetes diagnosis as well as treatment were found in the Visegrad Group (V4) countries. The difference between Poland, with the lowest score of 41 points, and the other countries is about 20-25 points. The main reasons for the low score are limited access to registered drugs due to lack of reimbursement or high reimbursement restrictions and a low proportion of patients treated with selected products from the GLP-1 group.
Cross-Country
General GAP for Diabetes Mellitus
Compliance with guidelines
Positive recommendations were found in clinical practice guidelines for 22 of the assessed molecules or their combinations, and a significant inequality between countries was observed in the V4 region. The availability of recommended drugs in the reimbursement framework is less than 50% in Poland and about 70-80% in the other countries.
From registration to reimbursement
Population burden
DALY* - Rate per 100k
*disability adjusted life-years
Target population
Diabetes type 2 prevalence
Estimated diabetes prevalence (GBD).
Drug access
Number of patientS treated (2023)
Drug access
POPULATION treated selected glp-1 (%)
Main issues
- The average time to reimbursement for diabetes drugs in the V4 countries is 2.6 years. The difference between the shortest and the longest mean time to reimbursement among the countries is 4.8 years.
- The uptake of selected GLP-1 drugs is low at less than 10% of the population with type II diabetes.
- DALY (disability adjusted life years) burden in the V4 countries, apart from Slovakia, is clearly higher than the European Union average. An increasing trend of DALY burden was observed in 1995-2019 in V4 countries, which is in line with the observations for the EU.
Project
We measured the gap in innovative drug access and diagnostics in selected therapeutic areas in the Visegrád (V4) countries (Poland, Hungary, Czechia and Slovakia).